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Epstein-Barr virus (EBV) replication contributes
to multiple human diseases, including infectious
mononucleosis, nasopharyngeal carcinoma, B cell
lymphomas, and oral hairy leukoplakia. We per-
formed systematic quantitative analyses of temporal
changes in host and EBVproteins during lytic replica-
tion to gain insights into virus-host interactions, using
conditional Burkitt lymphoma models of type I and II
EBV infection. We quantified profiles of >8,000
cellular and 69 EBV proteins, including >500 plasma
membrane proteins, providing temporal views of the
lytic B cell proteome and EBV virome. Our approach
revealed EBV-induced remodeling of cell cycle,
innate and adaptive immune pathways, including
upregulation of the complement cascade andprotea-
somal degradation of the B cell receptor complex,
conserved between EBV types I and II. Cross-com-
parison with proteomic analyses of human cyto-
megalovirus infection and of a Kaposi-sarcoma-
associated herpesvirus immunoevasin identified
host factors targeted by multiple herpesviruses. Our
results provide an important resource for studies of
EBV replication.INTRODUCTION
Epstein-Barr virus (EBV) is a gamma-herpesvirus that estab-
lishes persistent infection in >95% of adults worldwide. Two
distinct strains of EBV have been identified, referred to as type
I and II (Kieff and Rickinson, 2007). Following salivary transmis-Cell
This is an open access article undsion, EBV replicates in or translocates through epithelial cells
and infects tonsillar B cells to establish lifelong B cell infection
(Thorley-Lawson, 2015; Tugizov et al., 2013). Periodic viral reac-
tivation re-infects the tonsillar epithelium, in which further rounds
of lytic replication amplify the virus population that is secreted
into saliva (Kenney and Mertz, 2014; Laichalk and Thorley-Law-
son, 2005). EBV lytic reactivation is central to the virus life cycle
and to most EBV-related diseases.
EBV is the etiologic agent of infectious mononucleosis and is
closely linked to the pathogenesis of multiple human malig-
nancies, with 200,000 EBV-associated cancers reported annu-
ally (Cohen et al., 2011). Lytic viral replication is implicated in
the pathogenesis of nasopharyngeal carcinoma and oral hairy
leukoplakia (Chien et al., 2001; Tsai et al., 2013) and may
contribute to growth of B cell tumors, particularly in immunode-
ficiency (Arvey et al., 2012; Ma et al., 2011). The incidences of
EBV-related Hodgkin lymphoma continue to rise in individuals
with HIV infection despite antiretroviral therapy (Powles et al.,
2009).
Upon lytic reactivation, EBV genes are sequentially expressed
in immediate-early (IE), early (E,) and late (L) phases. The imme-
diate early transcription factors ZTA (encoded by BZLF1) and
RTA (encoded by BRLF1) jointly trigger the EBV lytic cycle.
EBV early genes are synergistically induced by ZTA and RTA
and encode the viral polymerase and replication machinery.
Late viral genes encode structural proteins that encapsidate
and mediate release of infectious virions (McKenzie and El-
Guindy, 2015).
mRNA expression profiling has provided important informa-
tion on the kinetics of viral gene expression upon lytic cycle in-
duction in Burkitt lymphoma cell lines (Koganti et al., 2015;
Yuan et al., 2006). Likewise, RNA sequencing (RNA-seq) of lym-
phoblastoid cell lines with varying degrees of lytic replication
provided insights into B cell and virus transcription patterns
induced by EBV reactivation (Arvey et al., 2012). However,Reports 19, 1479–1493, May 16, 2017 ª 2017 The Author(s). 1479
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post-transcriptional effects may substantially alter the host and
EBV proteome, and little is presently known about cell surface
remodeling during EBV lytic replication. The comparative effects
of type I and II EBV on human proteins are unknown.
We used tandem-mass-tag (TMT)-based MS3 mass spec-
trometry to perform quantitative temporal proteomic analysis
of EBV replication in human Burkitt lymphoma B cells latently
infected by type II EBV, prior to and at four time points after in-
duction of lytic replication (Weekes et al., 2014). Selective
plasmamembrane (PM) protein enrichment enabled quantitation
of global cell surface changes, without the need for specific an-
tibodies. We quantified 8,318 host proteins, including 550 PM
proteins and 69 EBV proteins, providing an in-depth temporal
view of the host and viral proteome during B cell replication.
Our analysis identified key host targets of EBV lytic replication,
including multiple immune pathways. Unexpectedly, an EBV
early factor targets the B cell receptor (BCR) complex for protea-
somal degradation. We found that host protein abundance was
similarly remodeled by type I EBV lytic replication in Burkitt
lymphoma cells, identifying evolutionarily conserved EBV B cell
targets. We further highlight host proteins co-targeted by multi-
ple human herpesviruses and provide an in-depth resource for
studies of EBV lytic replication.
RESULTS
Quantitative Temporal Viromic Analysis of EBV
Replication
We used the well-characterized type II EBV+ Burkitt lymphoma
cell line P3HR1 to quantify changes in PM and whole cell lysate
(WCL) protein expression by 10-plex TMT and MS3 mass spec-
trometry at three reference time points after induction of lytic
EBV replication (experiments WCL1 and PM1, Figure 1A).
Although it is difficult to induce viral replication in most latently
infected B cell lines, P3HR1 is highly permissive for induced
EBV lytic reactivation and exhibits low level spontaneous lytic
replication (Balachandran et al., 1986; Verma et al., 2009). To
ensure sufficient cells entered the EBV lytic replication cycle
for proteomic analysis, the P3HR1 line was engineered to ex-
press the EBV immediate early proteins ZTA and RTA fused to
a 4-hydroxy tamoxifen (4-HT)-dependent mutant estrogen re-
ceptor binding domain (ZHT andRHT, respectively) (Calderwood
et al., 2008; Chiu et al., 2013). The addition of 4-HT causes ZHT/
RHT nuclear translocation, triggering EBV lytic replication. As is
commonly observed, abortive lytic replication occurred in a frac-
tion of P3HR1 cells, in which ZTA/RTA do not trigger the full lytic
program and infectious particles are not produced (Chiu and
Sugden, 2016; Klein et al., 1974; Lin and Raab-Traub, 1987;
Miller et al., 1974). We therefore used flow cytometry to sort
4-HT-induced P3HR1-ZHT/RHT cells into fully lytic and abortive
lytic populations, based on expression of the EBV late cycle pro-
tein gp350, routinely achieving >40% of cells with PM gp350
expression (Figure 1A). We performed two additional replicate
proteomic experiments at 24, 48, and 72 hr after induction of
replication, which also enabled assessment of an early time point
of infection (15 hr, experiment WCL2), or a full time course of
analysis of mock 4-HT-induced parental control cell line, which
lacks the ZHT/RHT system (experiment WCL3) (Figure S1A).1480 Cell Reports 19, 1479–1493, May 16, 2017We quantified 8,249 human proteins across all three P3HR1
replicates (WCL1–3), including 6,307 proteins in all three repli-
cates. We additionally quantified 69 EBV proteins (63 in all repli-
cates). In experiment PM1, 550 PMproteins were quantified (Fig-
ures 1B, 1C, and S1B). We observed a high degree of correlation
between biological replicates (Figure S1C).
To validate our results in a second Burkitt lymphoma cell
system and to determine the extent to which proteome re-
modeling is conserved between type I and II EBV replication,
we next analyzed Akata cells (Figure 1A). Type I EBV+ Akata
cells are highly permissive for EBV lytic replication in response
to anti-immunoglobulin G (IgG) cross-linking (Takada and Ono,
1989). We examined biological duplicates at 0 and 48 hr after
Ig cross-linking and again used flow cytometry to sort induced
cells into fully lytic and abortive lytic populations, based on
EBV gp350 PM expression at 48 hr. To control for additional
effects of anti-IgG stimulation, we performed parallel analyses
of unstimulated and mock anti-IgG-induced EBV-negative
Akata control cells (Figure 1A). These analyses quantified
7,041 proteins. Biological replicates clustered tightly (Fig-
ure S1D), and a comparison of changes in gp350+ Akata and
P3HR1 cells revealed a high degree of correlation, with an r2
value of 0.70 (Figure 1D). All data are shown in Table S1,
where the worksheet ‘‘Plotter’’ is interactive, enabling genera-
tion of temporal graphs of PM and WCL expression of any of
the human and viral proteins quantified. Throughout this
manuscript, all analyses are based on the average values
from all analyzed replicates.
Quantitative Temporal Viromics Identifies Down- or
Upregulated Pathways
We used DAVID software (Huang et al., 2009) to identify path-
ways enriched among proteins significantly down- or upregu-
lated during lytic EBV replication in WCL and PM samples from
gp350+ P3HR1 or Akata cells. The term ‘‘antigen binding’’ or
‘‘B cell receptor signaling pathway’’ was enriched 14.7- to
22.3-fold among downregulated proteins compared to back-
ground (Figures 2A and S2A). Unexpectedly, the most highly
downmodulated host factors included multiple BCR compo-
nents: immunoglobulin M heavy chain (IgM) in P3HR1 and IgG
in Akata, signaling chains CD79A and CD79B (also called Iga
and Igb), and the immunoglobulin joining chain (IgJ), which
regulates multimerization of secretory IgM and IgA and is
necessary for their poly-Ig receptor-mediated transfer across
mucosal epithelium (Figures 1B, 1C, and 2B). Ig heavy-chain
class switching was unlikely to account for the observed result,
as we did not observe an accumulation of a different Ig heavy-
chain isotype in either P3HR1 or Akata. Among significantly up-
regulated proteins, DAVID analysis identified the complement
and blood coagulation pathways as highly significantly induced
(Figures 2A, 2C, and S2A).
We additionally validated our proteomic findings by immuno-
blot for key innate immune signaling components AIM2, a cyto-
solic receptor for double stranded DNA with roles in sensing
cytomegalovirus replication (Rathinam et al., 2010) and the tran-
scription factors IRF1, IRF4, and STAT2, which each have impor-
tant roles in antiviral responses (Figure S2B) (Blaszczyk et al.,
2016; Taniguchi et al., 2001).
Figure 1. Temporal Proteomic Profiling of EBV B Cell Lytic Replication
(A) Workflow of experiments WCL1 and PM1 in P3HR1 cells and a WCL experiment in Akata cells. Parental P3HR1 cells were analyzed at 0, 24, and 72 hr after
4-HT induction. P3HR1-ZHT/RHT cells were analyzed at 0, 24, 48, and 72 hr after 4-HT induction. Parental EBV-negative or EBV-positive Akata cells were
analyzed at 0 and 48 hr after induction. Cells were sorted by FACS in order to separate lytic gp350+ cells from abortive lytic gp350– cells.
(B) Volcano plot of proteins quantified in all three P3HR1WCL experiments (left panel) or the Akata WCL experiment (right panel). p values were estimated using a
two-tailed t test (left panel) or a one-way ANOVA (right panel). In each case, values were corrected for multiple hypothesis testing using the method of Benjamini
and Hochberg. Red dots: >2-fold change and p < 0.05. Orange dots: >2-fold change and p < 0.075. Green dots: viral proteins.
(C) Scatterplot of PM proteins quantified in experiment PM1. Significance Awas used to estimate p values (Cox andMann, 2008), which were corrected using the
method of Benjamini and Hochberg.
(D) Correlation between average fold change at 24 hr (gp350+/uninduced) in P3HR1 cells (replicates WCL1–3) and average fold change (gp350+/uninduced) in
Akata cell duplicates, for proteins quantified in all experiments.
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Figure 2. Enrichment Analysis Identifies EBV-Induced Downregulation of the BCR Complex and Upregulation of the Complement Pathway
(A) Functional enrichment within all proteins that were significantly (p < 0.05) downregulated an average of >2-fold by lytic EBV replication in P3HR1 replicates
WCL1–3 (red dots in Figure 1B, left panel). A background of all quantified proteins was used. A similar analysis was performed for proteins significantly upre-
gulated >2-fold. Dotted lines: p = 0.05. Components of each cluster are shown in Tables S2A and S2B.
(B) All BCR components quantified. Temporal plots (left-hand panels) illustrate data averaged over P3HR1 experiments WCL1–3. The parental cell line was
measured only in experiments WCL1 and WCL3. Right-hand panels show corresponding results from Akata cells. Error bars ±SEM (triplicates) or range
(duplicate). p values were calculated as described in Figure 1B: ****p < 0.0005, ***p < 0.005, **p < 0.05, *p < 0.075.
(C) Upregulated complement components, illustrated as described in (B).An Early-Expressed EBV Protein Targets the BCR
Complex for Degradation
IgM, CD79A, CD79B, and J chain were all downregulated by
15 hr of EBV lytic induction in gp350+ P3HR1 cells (Table S1).
We validated changes in IgM and CD79A by immunoblot.
Moderate IgM and CD79A loss were observed in gp350– cells
by the 72-hr time point (Figure 3A), which may reflect down-
regulation by an early-expressed EBV protein during abortive
replication in these cells. We additionally validated changes in
IgM by flow cytometry, both by 4-HT induction in P3HR1-ZHT/1482 Cell Reports 19, 1479–1493, May 16, 2017RHT cells and chemical induction in parental P3HR1 cells (Fig-
ures 3B and 3C).
EBV lytic reactivation typically occurs in B cells expressing
either IgM or class-switched IgG heavy chains. Induction of
EBV reactivation in IgG+ Akata cells by anti-Ig cross-linking or
by treatment with sodium butyrate led to robust downregulation
of IgG and CD79A/B (Figures 2 and 3D). Acyclovir inhibits
the viral polymerase, preventing EBV late gene expression
(Colby et al., 1980; Feighny et al., 1981). Acyclovir treatment
of 4-HT-induced P3HR1 cells did not appreciably affect IgM
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Figure 3. EBV Lytic Replication Targets the BCR Complex for Degradation
(A) Immunoblot of whole-cell extracts indicate downregulation of IgM and CD79A in gp350+ ZHT/RHT cells, representative of three independent experiments.
(B and C) Downregulation of IgM during P3HR1 lytic EBV replication confirmed by flow cytometry. Shown are representative plots for three independent ex-
periments of uninduced (B; left) and 48-hr 4-HT-induced P3HR1 (B; right) or of uninduced (C; left) and 48 hr 12-O-Tetradecanoylphorbol-13-Acetate (TPA)/
butyrate-induced P3HR1 (C; right).
(D) EBV lytic replication destabilizes the IgG BCR complex. EBV+ Akata B cells were induced to undergo lytic replication by TPA/butyrate treatment for 24 hr.WCL
from sorted gp350+ cells were immunoblotted are as indicated.downregulation, even though it prevented expression of the late
antigen gp350 (Figure 4A). These results are consistent with a
model in which an early-expressed EBV gene, conserved be-
tween type I EBV (Akata) and type II EBV (P3HR1) strains, targets
the BCR for degradation independently of heavy-chain isotype.
Lysosomal blockade had little effect on lytic replication-
induced loss of IgM; however, inhibition of the proteasome by
bortezomib stabilized IgM in gp350+ cells (Figures 4B–4D). By
immunofluorescence, we similarly observed IgM loss in 4-HT-
induced P3HR1-ZHT/RHT cells that was rescued by borte-
zomib, without appreciable effect on early antigen expression
(Figure 4E).
IgM distribution appeared distinct in control versus borte-
zomib-treated 4-HT-induced cells, suggesting accumulation in
an intracellular pool, for example a cytoplasmic aggresome (Fig-
ure 4E). To further test this possibility, we examined immunopuri-
fied P3HR1-ZHT/RHT IgM complexes from uninduced and
induced cells. EBV lytic replication in the presence of bortezomib
increased levels of poly-ubiquitin conjugates attached to im-
mune-purified IgM complexes (Figure 4F). Taken together, our
results suggest that an EBV early gene targets cell-surface andintracellular BCR pools for ubiquitin-mediated proteasomal
degradation.
EBV Lytic Replication Induces B Cell Complement
Pathway Expression
Complement proteins C3, C4A, and C7 were substantially upre-
gulated by EBV replication in P3HR1 and Akata cells, in addition
to C5 and C9 in P3HR1 (Figure 2C; Table S1). Complement
component expression was detectable by 24 hr after induction
and peaked at 48–72 hr. Similarly, C1R, and C4A were upregu-
lated at the PM of gp350+ but not gp350– P3HR1 cells (Fig-
ure 1C). To our knowledge, complement expression has not
previously been observed in B cells.
We excluded the possibility of an artifact due to deposition
of serum complement proteins from cell culture media via
qRT-PCR for C3 and C4A in gp350+ cells (Figure S2C). The clas-
sical pathway activator mannose activated serine protease 1
(MASP1) was similarly increased by EBV lytic replication (Fig-
ure S2C). Furthermore, polymorphisms in C3, C4A, and C5 pro-
tein sequences revealed that multiple identified peptides were of
human and not of bovine origin (Table S3). These data indicateCell Reports 19, 1479–1493, May 16, 2017 1483
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that EBV replication induces mRNA and protein expression of
multiple complement components, and that complement com-
ponents are deposited on lytic B cell PM. Complement induction
may be a host response to EBV infection or may instead play an
undefined role in EBV replication or spread, for example, through
recently appreciated intracellular roles in host metabolism (Hess
and Kemper, 2016). By contrast, lytic replication of the related
herpesvirus human cytomegalovirus (HCMV) did not induce
complement production in human fibroblasts (Weekes et al.,
2014).
EBV Lytic Program Effects on Host Cell-Cycle
Regulators
The EBV lytic cycle promotes a pseudo-late G1/S-phase to sup-
port EBV replication, through partially understood mechanisms
(Chiu et al., 2013; Hammerschmidt and Sugden, 2013; Kenney,
2007; Paladino et al., 2014). Enrichment analysis suggested
that multiple cyclin-dependent kinases (CDK) or CDK regulators
were downregulated during lytic replication (Figure 2A; Table
S2A), including the cyclin-dependent kinase CDK4, which phos-
phorylates retinoblastoma family proteins to promote G1/S
progression. A comprehensive search of our P3HR1 and Akata
data revealed additional downmodulated cell-cycle regulators
including tyrosine kinase WEE1 (Figure 5A), which inhibits entry
into mitosis (Matheson et al., 2016); the licensing factor CDT1,
which is a key component of the pre-replication complex and
p15, which binds to CDK4 and inhibits G1/S progression (Ha-
vens and Walter, 2011). The observed effects on each of these
key cell-cycle regulatory factorsmay contribute to establishment
of the pseudo-late G1/S phase environment.
mTOR promotes cell-cycle progression through S6K and
eIF4E pathways, though specific roles in EBV lytic replication
remain incompletely characterized (Adamson et al., 2014).
Interestingly, we observed the S6K target programmed cell
death 4 (PDCD4) to be among the most highly downregulated
protein by EBV replication in P3HR1 cells; a similar effect was
observed in Akatas (Figures 5B and 5C). Since S6K-mediated
phosphorylation triggers PDCD4 ubiquitination by the cullin
ubiquitin ligase b-TRCP (Dorrello et al., 2006), the observed
PDCD4 loss suggests that EBV lytic replication may activate
the S6K pathway. We confirmed that PDCD4 was stabilized
in 4-HT-induced P3HR1 cells by small molecule antagonists
of proteasome or cullin ubiquitin ligase activity (Figure 5D).
Since PDCD4 suppresses cap-dependent translation (Yang
et al., 2003), we used cap-dependent firefly and cap-inde-
pendent renilla luciferase reporters, revealing that EBV lytic
induction significantly increased cap-dependent translation
(Figure 5E).Figure 4. An EBV Early Factor Targets IgM for Proteasomal Degradati
(A–C) Flow cytometry of P3HR1-ZHT/RHT cells, treatedwith acyclovir (A), bortezo
for three independent experiments.
(D) IgM or GAPDH immunoblot analysis of WCL from P3HR1-ZHT/RHT treated
experiments.
(E) Immunofluorescence analysis of Hoechst stain, IgM, or EBV early antigen expre
Proteasome inhibition results in intracellular accumulation of IgM in early antigen
(F) Immunoblot analysis of poly-ubiquitin chains (poly-Ub) from WCL or IgM co
replication for 24 hr, in the absence or presence of bortezomib, as indicated. BloEBV-encoded LMP2A is a dedicated activator of mTOR in
latent EBV infection (Cen and Longnecker, 2015; Moody et al.,
2005) that is also expressed in the viral lytic phase (Yuan et al.,
2006), suggesting it may trigger PDCD4 loss. Interestingly, we
found that despite the absence of EBNA2 in P3HR1, LMP1,
and LMP2A expression were nonetheless robustly induced by
4-HT (Figure 5F). While EBNA2 drives LMP1 expression from
the ED-L1 promoter in EBV latency III, EBV lytic replication
may instead use the LT-R1 promoter located in the terminal re-
peats, which mediates LMP1/LMP2A expression in an EBNA2-
independent manner (Kieff and Rickinson, 2007). Immunoblot
analysis demonstrated that PDCD4 expression was markedly
reduced by stable LMP2A expression in P3HR1 cells (Figure 5G).
Likewise, inhibition of the LMP2A/mTOR pathway kinases SYK
by fostamatinib or PI3K by idelalasib, or blockade of mTOR itself
by rapamycin, each stabilized PDCD4 in 4-HT-induced P3HR1
cells (Figure 5H). Taken together, these results indicate that
LMP2A supports EBV lytic replication by de-repressing PDCD4
effects on cap-dependent translation. PDCD4 downregulation
may be of wider importance to other herpesviruses, as we previ-
ously found that HCMV also downregulates this protein (Weekes
et al., 2014).
Effects on B Cell Transcription Factor Networks
The physiological trigger for reactivation of latent EBV in B cells
remains elusive; however, EBV replication is thought to initiate
upon plasma cell differentiation (Laichalk and Thorley-Lawson,
2005). Interestingly, gene set enrichment analysis (GSEA) (Sub-
ramanian et al., 2005) identified enrichment of the plasma cell
network in gp350+ P3HR1 cells (Figures S3A and S3B). Further-
more, DAVID analysis (Huang et al., 2009) suggested that EBV
lytic replication downmodulated multiple B cell transcription
factors (TFs) which are known to be suppressed upon germinal
center B cell differentiation into plasma cells (Figure S4A; Table
S3A). For instance, BCL6, which is critical for the maintenance
of germinal center B cell fate, was decreased by 85% at
24 hr after induction of replication in P3HR1 and also significantly
decreased in gp350+ Akata cells (Figure S4A). CRISPR knockout
of the ubiquitin ligase FBXO11, which controls BCL6 steady-
state levels in uninfected B cells (Duan et al., 2012), did not inhibit
EBV-mediated BCL6 loss (Figure S4B). By contrast, BCL6
mRNA levels were significantly decreased by 24 hr after lytic in-
duction by 4-HT (Figure S4C). These results suggest that EBV
lytic replication blocks BCL6 expression prior to translation.
Similarly, Myc is repressed during plasma cell terminal dif-
ferentiation, and MYC levels were reduced by nearly 80% in
gp350+ P3HR1 and Akata cells by 24 hr. ETS1 and ID3 each
inhibit plasma cell differentiation (Nutt et al., 2015) and wereon
mib (B), or lysosome inhibitors (C), as indicated. Shown are representative plots
with bortezomib or lysosome inhibitors, representative of three independent
ssion in P3HR1 ZHT/RHT cells treatedwith 4-HT and bortezomib, as indicated.
+ cells.
mplexes immunopurified from P3HR1 ZHT/RHT cells, induced for EBV lytic
ts are representative of three independent experiments.
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similarly downregulated in gp350+ P3HR1 and Akata cells (Fig-
ure S4A). Notably, the deubiquitinase USP1 stabilizes ID3 (Wil-
liams et al., 2011), and USP1 was also suppressed by EBV lytic
replication (Table S1). A transcription module composed of IRF8
andSPI1/PU.1 limits plasma cell differentiation (Nutt et al., 2015),
and each was downmodulated in gp350+ P3HR1 and Akata cells
by 24 hr (Figure S4A; Table S1).
We observed significant upregulation in gp350+ cells of TFs
that have key roles in plasma cell development or terminal B
cell differentiation including IRF4, the IRF4 target ZBTB20, Fos,
and FosB (Table S1; Figure S4B) (Nutt et al., 2015). While plasma
cell differentiation stimulates EBV lytic replication, our data sug-
gest that EBV lytic replication in germinal-center-derived Burkitt
lymphoma B cells may, in turn, remodel the B cell TF network to
mimic key aspects of plasma cell differentiation.
Identification of PM and Whole-Cell Proteins Commonly
Targeted by Diverse Herpesviruses
Certain key proteins important in innate antiviral immunity are
known to be targeted by more than one, or sometimes multiple
viruses (Schoggins et al., 2011; Schreiner and Wodrich, 2013).
To identify proteins jointly targeted by EBV and other human her-
pesviruses, we combined our data with our previous analyses of
either temporal HCMV infection or of cell-surface proteins tar-
geted by the Kaposi’s-sarcoma-associated herpesvirus (KSHV)
viral ubiquitin E3 ligase K5 (Timms et al., 2013; Weekes et al.,
2014). We applied stringent filters to identify proteins that were
(1) regulated >2-fold in all experiments by both viruses; (2) regu-
lated by EBV as opposed to the 4-HT added to induce lytic-cycle
replication (Figure 6). Of 6,389 whole-cell proteins quantified in
both HCMV and EBV analyses, ten downregulated host factors
met all criteria, of which eight function in poly(A) RNA binding
and six are known to interact (Figures 6A–6C; Table S4).
A similar analysis of PM proteins downregulated by both EBV
and HCMV identified 12 proteins, enriched in molecules func-
tioning in synapse organization (Figures 6D–6F; Table S4). We
previously identified HCMV-induced downregulation of multiple
members of the protocadherin family and provided initial confir-
matory evidence that members of this family are activating nat-
ural killer (NK) ligands (Weekes et al., 2014). Protocadherin
gC3 was also downregulated during EBV infection (Figure 6E,
Table S4), in addition to three Neuroligins (NLGN1, 3, and 4X)
and Bone Morphogenetic Protein Receptor Type 1A (BMPR1A).
NLGN1, NLGN4X, and BMPR1A were also targeted by KSHV
K5 (Figure 6G; Table S4), suggesting that these molecules
may be of particular importance in herpesviral pathogenesis. A
recent report suggested the existence of an as-yet-unidentified
DNAM-1 ligand of particular importance for killing early-lytically(E) EBV lytic replication increases cap-dependent translation in P3HR1-ZHT/RH
firefly (FF) and cap-independent renilla luciferase reporter vector pFR_CrPV-xb
48 hr, and FF and renilla activity were quantified by dual luciferase assay. Shown
SEM values from three independent experiments. ***p < 0.001.
(F) LMP1 and LMP2A immunoblot of WCL from P3HR1 ZHT/RHT cells treated w
(G) LMP2A downregulates PDCD4. Immunoblot of WCL from uninduced P3HR1
independent experiments.
(H) Blockade of mTOR (rapamycin), PI3K (idelalasib), or SYK (fostamatinib) rescu
gp350+ cell WCL is as indicated. Blots are representative of three independent einfected B cells, whereas late-lytic cells are highly resistant to
killing (Williams et al., 2015). It is thus possible that one or
some of the protocadherins and neuroligins fulfill this function.
By stringent criteria, 48 proteins were commonly upregu-
lated by EBV and cytomegalovirus (CMV) (Figures 6D and S2;
Table S4). DAVID software suggested that this group was
particularly enriched in proteins with Interpro categories that
included ‘‘Unfolded protein binding,’’ ‘‘Endoplasmic reticulum
(ER) lumen,’’ ‘‘chaperone,’’ suggesting increased ER stress.
Further studies are required to determinewhether these changes
reflect directly targeted molecules versus non-specific effects of
herpesviral infection.
Quantitative Analysis of the EBV Virome
Prior proteomic analyses of EBV lytic protein expression have
identified 16 or 44 EBV proteins at single time points of viral re-
activation (Koganti et al., 2015; Traylen et al., 2015). A particular
benefit of our proteomic analysis is the opportunity not only to
identify viral proteins without specific reagents, but additionally
to quantify (1) their expression over time using TMT reporters
and (2) the relative abundance of each protein.
We quantified 63 canonical EBV-encoded proteins in all three
P3HR1 WCL samples. We used a ‘‘proteomic ruler’’ approach
(Wisniewski et al., 2014) to estimate cellular concentration (Fig-
ure 7A). We estimated that the most abundantly expressed
EBV protein, DNA polymerase processivity factor BMRF1, was
present at 1,000 times greater concentration than EBNA-3C,
the least expressed protein. The top three most abundant pro-
teins, BMRF1, BLRF2, and BALF2 accounted for 25% of the
overall EBV viral protein abundance, and, in total, tegument pro-
teins accounted for 39% of the total EBV protein abundance
(Figure 7A). The least expressed EBV proteins that we detected
included three Epstein-Barr nuclear antigens, which have roles in
transcription regulation. Notably, the P3HR1 EBV strain does not
encode the related EBNA2 TF and expresses a truncated form of
EBNA-LP (Palser et al., 2015). 57/63 of these proteins were also
quantified in Akata cells and displayed a similar relative abun-
dance (Figure 7B).
To determine whether non-canonical EBV-encoded polypep-
tides were expressed in gp350+ cells, we searched our data
against a six-frame translation of the P3HR1 genome (Palser
et al., 2015). We identified only a single non-canonical EBV poly-
peptide, which was quantified by two peptides in experiment
WCL1 and two peptides in WCL2. A further peptide from the
same open reading frame (ORF) was identified in experiment
WCL3; however, insufficient ions were present for quantitation
(Figure S5A). DNA sequence encoding a similar ORF is present
in the Akata genome (Grayson et al., 1985); however, peptidesT cells. Cells were transiently transfected with the cap-dependent translation
and rested for 24 hr. Cells were then left uninduced or were 4-HT-induced for
are mean fold changes of renilla-normalized FF luciferase activity. Median and
ith 4-HT, as indicated.
cells stably expressing control or HA-tagged LMP2A is representative of three
ed cellular PDCD4 during EBV lytic replication. Immunoblot of sorted P3HR1
xperiments.
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Figure 6. Whole-Cell and PM Proteins Co-regulated by EBV, CMV, and KSHV K5
(A) Overlap between EBV and CMV WCL data. 7,490 proteins were quantified in either CMV experiment WCL1 or WCL2 or both (Weekes et al., 2014). 6,389 of
these proteinswere additionally quantified in EBV experimentsWCL1–3. From this overlap, 1,083 proteins were downregulated either by EBV or CMV, of which 43
were downregulated by both viruses. This initial ‘‘non-stringent’’ filtering included proteins downregulated in (1) all of experimentsWCL1–3, (2) any combination of
two of three experiments, but not quantified in the third, and (3) any one of three experiments, but not quantified in the other two. Using ‘‘stringent’’ filtering, we
identified a subset of ten proteins downregulated in all three EBV and both CMV experiments, that were additionally downregulated at least 2-fold more than the
P3HR1 parental control, to exclude non-specific effects of tamoxifen treatment (Figure 2 and Experimental Procedures). Of the 19 proteins upregulated by both
viruses, only one (APOE) met our stringent criteria.
(B) DAVID analysis identified eight of ten stringently filtered proteins functioning in poly(A) RNA binding (p < 0.001), of which six are known to interact (STRING
database). Blue lines represent experimental evidence for physical binding, purple for catalysis, and black for reaction. Gray bars indicate evidence for co-
expression.
(C) Example plots of two of the ten proteins GNL3 and TXNIP. Left: EBV experiments WCL 1–3. Right: CMV Experiment WCL2.
(legend continued on next page)
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Figure 7. Characteristics of 63 Proteins
(A) Estimated cellular concentration of all 63 viral proteins quantified in all three P3HR1WCL samples (top panel). A ‘‘proteomic ruler’’ approach was used, which
uses the mass spectrometry signal of histones to scale other proteins of unknown concentration (Wisniewski et al., 2014). Protein concentrations were similarly
calculated for both Akata duplicates (bottom panel). Error bars ±SEM (top panel); ± range (bottom panel). NQ, not quantified. The concentration of BLRF2 was
estimated at 29,900 nM in Akata cells; however, the y axis extends only to 20,000 for ease of comparison with P3HR1 data.
(B) Correlation between average protein concentrations estimated from P3HR1 and Akata WCL.
(C) Identification of EBV proteins at the PM. Histogram of peptide ratios for all gene ontology (GO)-annotated proteins was quantified in experiment PM1. PM only,
not detected in any of experiments WCL1–3. PM annotation, plasma membrane, cell surface, extracellular, or short GO.
(D) Gene and protein names of all nine identified viral PM proteins.from this ORF were not identified in our Akata experiment. While
additional EBV genesmay exist in clinical isolates, our results are
consistent with the hypothesis that the majority of P3HR1 strain
EBV protein-coding genes have been identified.(D) Analysis of co-regulated PMproteins.We used similar non-stringent filter as de
PM2. Stringent filtering excluded non-specific effects of tamoxifen treatment on
(E) 12/16 downregulated proteins met our stringent criteria, of which the top four l
met our stringent criteria.
(F) Temporal proteomic analysis of NLGN4X and PCDHGC3. Left: EBV experime
(G) Coregulation of PM proteins by EBV and the KSHV K5 gene. Nine proteins me
(green text) (E).We recently described a method of classification in which
herpesviral proteins are grouped according to their temporal
profiles (Weekes et al., 2014) and used this with data from exper-
iment WCL2 to assign EBV proteins to four temporal classestailed in (A), comparing EBV experiment PM1with HCMV experiments PM1 and
ly, as there was no second temporal replicate for the EBV PM experiment.
isted functioned in synapse organization (p < 0.05). 46/48 upregulated proteins
nts WCL 1–3. Right: CMV experiment WCL 2.
t the stringent filter (D), of which three were additionally downregulated by CMV
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(Figures S5B–S5D). The Tp1 cluster contains multiple members
of the EBV viral preinitiation complex, which activates expres-
sion of most EBV late genes from newly replicated viral DNA
(Aubry et al., 2014; Djavadian et al., 2016). The Tp2 cluster
included proteins important in inhibition of host innate immunity,
and multiple tegument, capsid, and envelope proteins were pre-
sent in the later-expressed Tp3 class.
Abundant viral proteins present at the PM may be EBV vac-
cine and/or therapeutic antibody targets. We used a validated
filtering strategy that relies on the ratio of PM to WCL peptides
(Weekes et al., 2014) to identify nine high-confidence EBV PM
proteins (Figures 7C and 7D; Experimental Procedures). These
included four of five EBV glycoproteins involved in B cell entry:
gp350, gp42 (encoded by BZLF2), gB, and gH (Hutt-Fletcher,
2015). The single-pass type I membrane protein BDLF3, impli-
cated in cell surface major histocompatibility complex (MHC)
class I and II downregulation (Quinn et al., 2015) and cell
surface heparin sulfate binding (Chesnokova et al., 2016),
was present at the P3HR1 PM. We additionally detected type
II membrane protein BDLF2 and the multispanning membrane
protein BMRF2, which form a complex implicated in epithelial
attachment and possibly intercellular spread (Gore and Hutt-
Fletcher, 2009; Hutt-Fletcher, 2015). Five EBV glycoproteins
were not detected, including glycoprotein gL, the secreted fac-
tor BARF1, the tegument protein BLRF2, the 7-transmbrane
segment G-protein-coupled receptor BILF1, and BILF2, whose
function remains unknown. Additional membrane proteins may
not have been detected given their high degree of hydropho-
bicity, including the multipass proteins LMP1 and LMP2A.DISCUSSION
EBV establishes latency upon B cell infection. Global studies of
EBV lytic reactivation have been limited by technical hurdles,
such as the ability to obtain sufficient samples for systematic
proteomic and viromic analysis. Most large-scale studies have
therefore focused on mRNA transcription profiles (Concha
et al., 2012; Koganti et al., 2015; Traylen et al., 2015; Yuan
et al., 2006), single time-point analyses of a subset of the viral
proteome, or on analyses of subsets of host proteins (Koganti
et al., 2015; Traylen et al., 2015). Technological advances in
mass spectrometry have enabled us now to provide the most
complete to date temporal study of changes in the host prote-
ome and EBV virome during lytic B cell replication. Collectively,
our study provides a valuable resource for studies of EBV lytic
replication and lays the foundation for future studies in ex vivo
B cells, where limiting cell quantities preclude global proteomic
analysis at present.
Our analysis unexpectedly revealed that an early EBV factor
targets the BCR complex for proteasomal degradation. PM
and WCL proteomic analysis, as well as fluorescence-activated
cell sorting (FACS) and immunofluorescence, suggests that both
PM and intracellular BCR pools are targeted. Further studies are
required to identify whether soluble Ig isoforms are also targeted,
and to characterize the ubiquitin-proteasome pathway by which
EBV downmodulates these BCR pools. One candidate is EBV
BDLF3, an early factor that targets cell-surface and intracellular1490 Cell Reports 19, 1479–1493, May 16, 2017MHC class I molecules for ubiquitin-mediated proteasome
degradation (Quinn et al., 2015).
Targeting of the BCR during EBV B cell lytic replication may be
conserved across EBV strains, since we observed a similar de-
gree of Ig loss in Akata and P3HR1 B cells, which harbor type I
and II EBV, respectively. We hypothesize that EBV targets the
BCR to facilitate EBV B cell replication for one of the following
reasons. First, a subset of lytic B cells may produce Ig reactive
to antigen present on virions. BCR degradation would then
enable EBV to avoid becoming trapped by binding to these
antibodies within the secretory pathway or at the cell surface.
Second, EBV lytic replication is thought to occur in tonsillar
plasma cells, which are loaded with Igs. Plasma cells secrete
Igs at the rate of approximately 2,000 molecules per second
(Hibi and Dosch, 1986). Ig degradation may therefore shift meta-
bolic capacity away from secretion of Ig and toward production
of infectious virions, in order to prevent competition for amino
acid resources. Third, multiple herpesviruses encode Ig Fc-bind-
ing proteins that enable lytic cells to evade antibody responses
(Hook and Friedman, 2007). Degradation of endogenous Ig
may prevent an EBV-encoded Fc receptor from being fully occu-
pied by the Fc regions of plasma cell Ig, in particular, if EBV also
downregulates soluble antibody.
Additional pathways were selectively downregulated during
lytic viral reactivation, including multiple components of the
cell-cycle machinery. Protein downregulation in some cases
may involve the EBV host shutoff protein BGLF5, which was
expressed early in infection (Table S1; Figure S5B). As BGLF5
accelerates host mRNA turnover (Rowe et al., 2007), it is likely
either that BGLF5 selectively destabilizes these host mRNAs,
or that targeted proteins are downregulated via an alternative
route, as seen for the BCR complex. EBV-encoded microRNAs
(miRNAs) also suppress expression of multiple host targets
(Skalsky and Cullen, 2015). An important future goal will be to
systematically compare changes in mRNA and protein abun-
dances triggered by EBV lytic replication, in order to more fully
define the extent to which EBV exerts post-transcriptional ef-
fects on host target gene expression.
Multiple aspects of the EBV life cycle are intimately linked
with the complement system. The EBV entry protein gp350
has homology with the C3 complement component cleavage
product C3dg (Nemerow et al., 1989). gp350 and C3dg each
bind to CD21, a key B cell complement receptor. The
Epstein-Barr virion accelerates decay of the alternative
pathway C3 convertase (Mold et al., 1988). We now report
that EBV B cell lytic reactivation stimulates complement
component production. Despite its recognized roles in host de-
fense, complement components are increasingly implicated in
regulation of metabolism and cellular survival. Surprisingly,
intracellular roles have recently been identified for complement,
including in regulation of T cell metabolic networks and homeo-
static survival (Hess and Kemper, 2016). Intracellular comple-
ment roles in BCL2 and Fas upregulation have been described
in T cells (Kolev et al., 2015; Lalli et al., 2008). Similarly, KSHV
latency proteins exploit the complement system to promote
endothelial cell survival (Lee et al., 2014). Further studies will
be required to determine whether complement upregulation
represents a host defense to EBV, or EBV subversion of this
immune pathway to activate metabolic or cell survival path-
ways that support B cell virion production.
EBV establishes latent infection upon B cell entry, and the
tonsillarplasmacell populationharbors lyticEBV inexvivostudies.
These observations support amodel inwhichplasmacell differen-
tiationprovidesacue that stimulatesEBV replication. Interestingly,
our findings suggest that EBV lytic replication may likewise facili-
tate plasma cell differentiation, through suppression of TFs that
maintain germinal center state and through upregulation of factors
that promote plasmacell differentiation.Key germinal centerB cell
TFs downmodulated by EBV lytic replication included BCL6,
ETS1, IRF8, ID3, and MYC, whereas the antibody secreting cell-
inducing TFs IRF4, ZBTB20, FOS, and FosB were strongly upre-
gulated. Thus, rather than passively activating as a bystander of
plasma cell differentiation, EBV may play a more active role in
remodeling the B cell environment to favor lytic replication.
To persist in an infected individual lifelong, herpesviruses have
developed multiple strategies to modulate innate and adaptive
immunity. One benefit is that we can use the overlap between
proteins targeted by different herpesviruses to discover mole-
cules particularly important in host defense. By comparing
EBV, CMV, and KSHV, we identified downregulation of several
members of the same protein family including Neuroligins and
human leukocyte antigen (HLA) molecules. EBV and CMV both
targeted Protocadherin gC3 for downregulation suggesting
that this molecule, other members of the same family, and the
Neuroligins might be activating NK ligands, as we previously
demonstrated for Protocadherin FAT1 (Weekes et al., 2014).
The quantitation of80%of canonical EBV proteins in a single
experiment provides a significant technological advance and
enabled systematic temporal analysis of g-herpesviral protein
expression. Clues as to viral mechanism may derive from corre-
lation of viral and cellular protein expression patterns from our
temporal analysis. Early-downregulated host proteins may be
targeted by one of the earliest Tp1 or Tp2 classes of viral protein.
Our protein temporal classes were complementary to classical
IE/E/L nomenclature and provide an increased level of resolution
in combination with transcriptional data. In general, we observed
low-level expression of viral proteins in gp350– cells compared to
gp350+ cells, depending on the time point studied after induction
(Figure S5C). Many of the host protein changes we observed
were correspondingly regulated to a lesser extent in gp350– cells
(Figures 2B, S2B, and 5A; Table S1), suggesting that proteins
expressed in abortive lytic P3HR1 or Akata cells likely account
for these changes.
Innovative strategies are required to treat EBV-related dis-
eases. Our quantitation of the relative abundance of cell sur-
face EBV viral proteins may enable rational design of therapeutic
monoclonal antibodies for preliminary studies and enhance ef-
forts to develop an EBV vaccine. Collectively, our studies provide
a rich resource for further analyses of EBV B cell lytic replication,
and herpesviral infections more widely, and identify multiple viral
targets for additional analysis.EXPERIMENTAL PROCEDURES
Brief descriptions of key experimental procedures are provided below. For
complete details, see Supplemental Experimental Procedures.WCL and PM Preparation
PM profiling was performed as previously described (Weekes et al., 2014) with
minor modifications. FACS cells were washed twice with ice-cold PBS, fol-
lowed by oxidation of sialic acid residues with sodium-meta-periodate.
Plasma-membrane glycoproteins were selectively labeled with aminooxy-
biotin. The reaction was quenched, cell numbers were normalized, and then
cells were lysed in Triton X-100.
For whole-proteome samples, cells were washed, lysed in 6 M guanidine/
50 mM HEPES buffer, and then vortexed, sonicated, and centrifuged. Protein
concentrations were determined by bicinchoninic acid assay (BCA).
Protein Isolation and Peptide Labeling with Tandem Mass Tags
TMT-based analysis was performed as described previously (Weekes et al.,
2014). Alkylated and reduced proteins were digested into peptides, which
were labeled with TMT reagents, and fractions generated from combined pep-
tide samples strong cation exchange (PM samples) or high pH reverse-phase
high-performance liquid chromatography (HPLC).
Mass Spectrometry and Data Analysis
We performed mass spectrometry as described previously using an Orbitrap
Fusion or Orbitrap Lumos (Weekes et al., 2014) and quantified TMT reporter
ions from the MS3 scan. Peptides were identified and quantified using a Se-
quest-based in-house software pipeline. A combined database was searched,
consisting of human, P3HR1 and Akata strains of EBV, all ORFs from six-frame
translations of P3HR1 andAkata, and common contaminants. Peptide-spectral
matches were filtered to a 1% false discovery rate (FDR) using linear discrimi-
nant analysis in conjunction with the target-decoy method (Huttlin et al.,
2010). The resulting dataset was further collapsed to a final protein-level FDR
of 1%. Protein assembly was guided by principles of parsimony.Where all pep-
tidespectralmatches (PSMs) fromagivenEBVprotein couldbeexplainedeither
byacanonical geneoranORF from thesix-frame translation, thecanonical gene
was picked in preference. Proteins were quantified by summing TMT reporter
ion counts across all matching PSM after filtering based on isolation specificity.
Reverse and contaminant proteins were removed, and protein quantitation
values were exported for normalization and further analysis in Excel.
Contact for Reagent and Resource Sharing
Further information and reagent requests may be directed to the correspond-
ing authors.
ACCESSION NUMBERS
The accession number for the mass spectrometry proteomics data reported
in this paper is ProteomeXchange Consortium PRIDE: PXD006317 (Vizcaı´no
et al., 2016).
SUPPLEMENTAL INFORMATION
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